Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00983996
Recruitment Status : Completed
First Posted : September 24, 2009
Last Update Posted : September 24, 2009
Sponsor:
Information provided by:
Mylan Pharmaceuticals

Brief Summary:
The objective of this study is to investigate the bioequivalence of Mylan's alendronate sodium 10 mg tablets to Merck's Fosamax 10 mg tablets following a single, oral 40 mg (4 x 10 mg) dose administration under fasting conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Alendronate Sodium Tablets, 10 mg Drug: Fosamax Tablets, 10 mg Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Single-Dose Fasting In Vivo Bioequivalence Study of Alendronate Sodium Tablets (10 mg; Mylan) and Fosamax Tablets (10 mg; Merck) in Healthy Volunteers
Study Start Date : June 2002
Actual Primary Completion Date : July 2002
Actual Study Completion Date : July 2002

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1
Alendronate Sodium Tablets, 10 mg
Drug: Alendronate Sodium Tablets, 10 mg
10 mg, single-dose fasting

Active Comparator: 2
Fosamax Tablets, 10 mg
Drug: Fosamax Tablets, 10 mg
10 mg, single-dose fasting




Primary Outcome Measures :
  1. Bioequivalence [ Time Frame: urine collection up to 36 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy, adult subjects, 18 years and older
  • able to swallow medication

Exclusion Criteria:

  • institutionalized subjects
  • history of any significant disease
  • use of any prescription or OTC medications within 14 days of start of study
  • received any investigational products within 30 days prior to start of study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00983996


Locations
Layout table for location information
United States, North Dakota
PRACS Insitute Ltd.
Fargo, North Dakota, United States, 58104
Sponsors and Collaborators
Mylan Pharmaceuticals
Layout table for additonal information
Responsible Party: Wayne Talton, Mylan Inc.
ClinicalTrials.gov Identifier: NCT00983996    
Other Study ID Numbers: ALEN-0243
First Posted: September 24, 2009    Key Record Dates
Last Update Posted: September 24, 2009
Last Verified: September 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Alendronate
Bone Density Conservation Agents
Physiological Effects of Drugs